Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacology and pharmacokinetics of imatinib in pediatric patients.
Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E. Suttorp M, et al. Among authors: millot f. Expert Rev Clin Pharmacol. 2018 Mar;11(3):219-231. doi: 10.1080/17512433.2018.1398644. Epub 2017 Nov 6. Expert Rev Clin Pharmacol. 2018. PMID: 29076384 Review.
Management of chronic myeloid leukemia in childhood.
Suttorp M, Eckardt L, Tauer JT, Millot F. Suttorp M, et al. Among authors: millot f. Curr Hematol Malig Rep. 2012 Jun;7(2):116-24. doi: 10.1007/s11899-012-0113-6. Curr Hematol Malig Rep. 2012. PMID: 22395816 Review.
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F; International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee. de la Fuente J, et al. Among authors: millot f. Br J Haematol. 2014 Oct;167(1):33-47. doi: 10.1111/bjh.12977. Epub 2014 Jun 30. Br J Haematol. 2014. PMID: 24976289 Free article.
Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.
Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Sirvent N, Yakouben K, Schmitt C, Gandemer V, Reguerre Y, Couillault G, Mechinaud F, Cayuela JM. Millot F, et al. Blood. 2014 Oct 9;124(15):2408-10. doi: 10.1182/blood-2014-05-578567. Epub 2014 Aug 28. Blood. 2014. PMID: 25170123 Free article. Clinical Trial.
Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Pritchard-Jones K, et al. Lancet. 2015 Sep 19;386(9999):1156-64. doi: 10.1016/S0140-6736(14)62395-3. Epub 2015 Jul 9. Lancet. 2015. PMID: 26164096 Free article. Clinical Trial.
189 results